Adverse effects of bronchodilators
Pro Research Analysisby 
Searched over 200M research papers
Adverse Effects of Bronchodilators: A Comprehensive Overview
Cardiovascular Adverse Effects of Bronchodilators
Bronchodilators, commonly used to manage asthma and chronic obstructive pulmonary disease (COPD), can have significant cardiovascular side effects, particularly in older adults. Beta-adrenoceptor agonists (β-agonists) are known to cause inotropic and chronotropic effects, which can lead to arrhythmias, cardiomyopathy, and myocardial ischemia. These drugs can also cause electrolyte disturbances that contribute to arrhythmias and are associated with tremors, tolerance, poor disease control, and even sudden life-threatening exacerbations1. Additionally, long-term use of β-agonists has been linked to osteoporosis due to the presence of functional β2-adrenoceptors in osteoblasts1.
Neurological and Cognitive Effects
Inhaled anticholinergics, while generally well-tolerated, can cause dry mouth, pupillary dilation, blurred vision, and acute glaucoma due to the escape of droplets from nebulizer masks. These drugs can also lead to paradoxical bronchoconstriction and have central effects, notably impairing cognitive function1. Theophylline, another bronchodilator, is limited by its adverse effects, including gastrointestinal symptoms, palpitations, arrhythmias, and rare cases of myocardial infarction and seizures. It requires close monitoring due to its interaction with other medications and its primary metabolism in the liver1.
Dermatological and Systemic Reactions
A retrospective analysis in Italy found that bronchodilators were responsible for 18.5% of adverse drug reactions (ADRs) in hospitalized patients, with theophylline being the most implicated drug. Skin reactions were the most common ADRs, affecting 47.7% of cases. Withdrawal of the suspected drug led to recovery in 86% of cases, highlighting the importance of drug surveillance in identifying and managing ADRs2.
Pediatric Considerations
In infants with bronchiolitis, bronchodilators such as albuterol and salbutamol do not improve clinical outcomes and are associated with adverse effects like tachycardia. Studies have shown that nebulized beta-agonist treatment increases heart rate, adding stress to infants without documented benefits3.
Combination Therapy and Dosage Concerns
Combining bronchodilators like terbutaline and aminophylline can enhance bronchodilation but also increases the frequency of adverse side effects. High-dose combinations produce greater bronchodilation but also more side effects, suggesting that lower doses might be preferable for patients experiencing intolerable side effects from high doses of either drug alone4.
Long-Term Use and Disease Progression
Long-term use of bronchodilators without anti-inflammatory medication can worsen asthma and COPD control. Studies have shown that continuous bronchodilator treatment is associated with a higher annual decline in lung function and increased exacerbation rates. Adding inhaled corticosteroids can decelerate or reverse this unfavorable disease course7 9.
Comparative Safety of Long-Acting Bronchodilators
A population-based study comparing long-acting beta2-agonists (LABA) and the anticholinergic tiotropium found no significant difference in the risk of cardiovascular events between the two drugs. However, the incidence of pneumonia was higher with LABA, likely due to the inhaled corticosteroids present in many LABA inhalers8.
Short-Acting Bronchodilators in Acute Exacerbations
Short-acting bronchodilators (SABD) are commonly used for acute exacerbations of COPD in hospital settings. However, higher doses of SABD are associated with increased cardiac side effects, such as tachycardia, without additional clinical benefits compared to lower doses10.
Conclusion
Bronchodilators, while effective in managing respiratory conditions, come with a range of adverse effects that can impact cardiovascular, neurological, dermatological, and systemic health. Careful monitoring, appropriate dosing, and the use of combination therapies with anti-inflammatory medications can help mitigate these risks and improve patient outcomes.
Sources and full results
Most relevant research papers on this topic
Potential Adverse Effects of Bronchodilators in the Treatment of Airways Obstruction in Older People
Bronchodilators can cause more adverse effects in older people due to pharmacodynamic and pharmacokinetic changes, drug-disease interactions, and potential cardiovascular risks.
Highly CitedRetrospective analysis of adverse drug reactions to bronchodilators observed in two pulmonary divisions of Catanzaro, Italy.
Bronchodilators are a common cause of adverse drug reactions in hospitalized patients, with skin being the most susceptible system, and drug surveillance can effectively identify these events.
Observational StudyAdverse effects of bronchodilators in infants with bronchiolitis.
Bronchodilators in infants with bronchiolitis increase heart rate, causing additional stress without documented evidence of benefit, and should be used cautiously due to potential adverse effects.
Meta-AnalysisBronchodilator effects of terbutaline and aminophylline alone and in combination in asthmatic patients.
Combining high doses of theophylline and terbutaline can improve asthma control, while lower doses can be used for patients experiencing intolerable side effects from either drug alone.
RCTHighly CitedA PROSPECTIVE OBSERVATIONAL STUDY ON DISTRIBUTION PATTERN OF ADVERSE EFFECTS OF BRONCHODILATORS AMONG BRONCHIAL ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE PATIENTS IN A TERTIARY CARE TEACHING HOSPITAL IN A RURAL AREA OF KANCHEEPURAM DISTRICT
Inhalational forms of longer acting beta-2 agonists were better tolerated by patients with bronchial asthma and chronic obstructive pulmonary disease, with no observable adverse effects.
Observational StudyAdverse Reactions to β2-Agonist Bronchodilators
2-agonists are safe and effective bronchodilators with reversible side effects, and their use in inhaled form minimizes side effects.
Slowing the Deterioration of Asthma and Chronic Obstructive Pulmonary Disease Observed during Bronchodilator Therapy by Adding Inhaled Corticosteroids: A 4-Year Prospective Study
Inhaled corticosteroids can slow down the decline in lung function and improve symptoms in asthma and COPD patients experiencing worsening during bronchodilator therapy alone.
Observational StudyHighly CitedLong‐Acting Bronchodilator Initiation in COPD and the Risk of Adverse Cardiopulmonary Events: A Population‐Based Comparative Safety Study
COPD treatment initiation with tiotropium does not increase cardiovascular risk in the first year, while the risk of pneumonia is higher with LABA, likely due to inhaled corticosteroids in LABA inhalers.
Observational StudyDo bronchodilators adversely affect the prognosis of bronchial hyperresponsiveness?
Bronchodilators may have adverse effects on the prognosis of bronchial hyperresponsiveness when used alone, but their combined use with anti-inflammatory drugs may have even more beneficial effects.
Short-acting bronchodilators for the management of acute exacerbations of chronic obstructive pulmonary disease in the hospital setting: systematic review
Higher doses of short-acting 2-agonists for acute exacerbations of chronic obstructive pulmonary disease (AECOPD) showed no additional benefits compared to lower doses, but a small increase in adverse events.
Systematic Review
Very Rigorous Journal